ACK1/TNK2 Regulates Histone H4 Tyr88-phosphorylation and AR Gene Expression in Castration-Resistant Prostate Cancer.
Cancer Cell 2017 Jun;31(6):790-803.e8
Drug Discovery Department, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL 33612, USA; Department of Oncological Sciences, University of South Florida, Tampa, FL 33612, USA. Electronic address:

Proteome-wide Profiling of Clinical PARP Inhibitors Reveals Compound-Specific Secondary Targets.
Cell Chem Biol 2016 Dec 17;23(12):1490-1503. Epub 2016 Nov 17.
Department of Drug Discovery, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.

CD4+ T cell STAT3 phosphorylation precedes acute GVHD, and subsequent Th17 tissue invasion correlates with GVHD severity and therapeutic response.
J Leukoc Biol 2015 Apr 6;97(4):807-19. Epub 2015 Feb 6.
Departments of *Blood and Marrow Transplantation, Immunology, Hematopathology and Laboratory Medicine, Drug Discovery, and Biostatistics, Analytic Microscopy Core, H. Lee Moffitt Cancer Center, Tampa, Florida, USA.

GSK3 alpha and beta are new functionally relevant targets of tivantinib in lung cancer cells.
ACS Chem Biol 2014 Feb 20;9(2):353-8. Epub 2013 Nov 20.
Department of Drug Discovery, ‡Department of Thoracic Oncology, and §Molecular Oncology and Proteomics, H. Lee Moffitt Cancer Center & Research Institute , Tampa, Florida 33612-9497, United States.

17beta-hydroxysteroid dehydrogenase Type 1, and not Type 12, is a target for endocrine therapy of hormone-dependent breast cancer.
Int J Cancer 2008 May;122(9):1931-40
Department of Endocrinology and Metabolic Medicine and Sterix Ltd., Imperial College London, St. Mary's Hospital, London W2 1NY, United Kingdom.

Focused libraries of 16-substituted estrone derivatives and modified e-ring steroids: inhibitors of 17beta-hydroxysteroid dehydrogenase type 1.
ChemMedChem 2006 Apr;1(4):464-81
Medicinal Chemistry, Department of Pharmacy and Pharmacology and Sterix Ltd., University of Bath, Claverton Down, Bath, and St. Mary's Hospital, London, UK.